BMRN - BioMarin Pharmaceutical Inc Stock Price, Fair Value and News

81.80USD-0.78 (-0.94%)Market Closed

Market Summary

USD81.80-0.78

Market Closed

-0.94%

BMRN Alerts

4 major insider sales recently.

Big jump in Earnings (Y/Y)

BMRN Stock Price

View Fullscreen

BMRN RSI Chart

BMRN Valuation

Market Cap

15.5B

Price/Earnings (Trailing)

75.6

Price/Sales (Trailing)

6.28

EV/EBITDA

44.71

Price/Free Cashflow

85.42

BMRN Price/Sales (Trailing)

BMRN Profitability

Operating Margin

79.22%

EBT Margin

9.60%

Return on Equity

4.05%

Return on Assets

2.99%

Free Cashflow Yield

1.17%

BMRN Fundamentals

BMRN Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

8.79%

Rev. Growth (Qtr)

0.41%

BMRN Earnings

Earnings (TTM)

205.5M

Earnings Growth (Yr)

74.35%

Earnings Growth (Qtr)

335.15%

Breaking Down BMRN Revenue

Last 7 days

-1.8%

Last 30 days

-6.3%

Last 90 days

-7.2%

Trailing 12 Months

-14.4%

How does BMRN drawdown profile look like?

BMRN Financial Health

Current Ratio

2.74

Debt/Equity

0.12

Debt/Cashflow

0.47

BMRN Investor Care

Shares Dilution (1Y)

1.16%

Diluted EPS (TTM)

1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.5B	0	0	0
2023	2.2B	2.2B	2.3B	2.4B
2022	1.9B	1.9B	2.0B	2.1B
2021	1.8B	1.9B	1.8B	1.8B
2020	1.8B	1.8B	1.9B	1.9B
2019	1.5B	1.5B	1.6B	1.7B
2018	1.4B	1.4B	1.5B	1.5B
2017	1.2B	1.2B	1.3B	1.3B
2016	923.7M	973.7M	1.0B	1.1B
2015	801.0M	859.3M	891.7M	889.9M
2014	572.1M	627.1M	666.8M	749.6M
2013	512.0M	524.8M	533.5M	548.5M
2012	448.6M	461.9M	476.6M	500.7M
2011	400.8M	419.5M	435.1M	441.4M
2010	335.6M	344.8M	361.7M	376.3M
2009	0	305.9M	315.3M	324.7M
2008	0	0	0	296.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BioMarin Pharmaceutical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	guyer charles greg	sold (taxes)	-366,034	82.44	-4,440	evp, chief technical officer
May 02, 2024	davis george eric	acquired	116,735	63.1	1,850	evp, chief legal officer
May 02, 2024	ajer jeffrey robert	sold	-414,550	82.91	-5,000	evp, chief commercial officer
May 02, 2024	davis george eric	sold	-157,268	85.01	-1,850	evp, chief legal officer
Apr 30, 2024	davis george eric	acquired	20,662	68.646	301	evp, chief legal officer
Apr 30, 2024	guyer charles greg	acquired	16,818	68.646	245	evp, chief technical officer
Apr 30, 2024	ajer jeffrey robert	acquired	20,593	68.646	300	evp, chief commercial officer
Apr 12, 2024	bienaime jean jacques	sold	-1,825,200	91.26	-20,000	-
Apr 12, 2024	bienaime jean jacques	acquired	1,262,000	63.1	20,000	-
Apr 11, 2024	bienaime jean jacques	acquired	1,262,000	63.1	20,000	-

Which funds bought or sold BMRN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	OPPENHEIMER & CO INC	added	70.49	145,120	411,721	0.01%
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	reduced	-32.41	-987,594	1,559,630	0.01%
May 07, 2024	MONTAG A & ASSOCIATES INC	unchanged	-	-309	2,970	-%
May 07, 2024	Headlands Technologies LLC	added	344	373,625	497,139	0.12%
May 07, 2024	SEI INVESTMENTS CO	added	1.97	-1,242,970	15,032,100	0.02%
May 07, 2024	MEEDER ASSET MANAGEMENT INC	new	-	6,813	6,813	-%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	unchanged	-	-187,000	4,543,000	0.01%
May 07, 2024	SEI INVESTMENTS CO	unchanged	-	-26,512	644,054	-%
May 07, 2024	OPPENHEIMER ASSET MANAGEMENT INC.	reduced	-49.5	-146,427	148,267	-%
May 07, 2024	Washington Trust Advisors, Inc.	unchanged	-	-1,443	13,888	-%

Are Funds Buying or Selling BMRN?

Are funds buying BMRN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BMRN

No. of Funds

Unveiling BioMarin Pharmaceutical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	dodge & cox	7.4%	13,994,063	SC 13G/A
Feb 13, 2024	vanguard group inc	9.58%	18,048,557	SC 13G/A
Feb 12, 2024	primecap management co/ca/	9.78%	18,414,374	SC 13G/A
Feb 09, 2024	capital research global investors	5.7%	10,774,641	SC 13G
Jan 26, 2024	blackrock inc.	7.8%	14,740,836	SC 13G/A
Feb 14, 2023	dodge & cox	7.7%	14,383,663	SC 13G/A
Feb 13, 2023	capital research global investors	3.0%	5,651,001	SC 13G/A
Feb 09, 2023	primecap management co/ca/	9.46%	17,580,859	SC 13G/A
Feb 09, 2023	vanguard group inc	9.34%	17,365,080	SC 13G/A
Feb 03, 2023	blackrock inc.	8.2%	15,206,690	SC 13G/A

Recent SEC filings of BioMarin Pharmaceutical Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 02, 2024	144	Notice of Insider Sale Intent
May 02, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	10-Q	Quarterly Report
Apr 24, 2024	8-K	Current Report
Apr 23, 2024	8-K	Current Report
Apr 15, 2024	4	Insider Trading
Apr 12, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to BioMarin Pharmaceutical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

BioMarin Pharmaceutical Inc News

Latest updates

BioMarin Pharmaceutical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0.4%	649	646	581	595	596	538	505	534	519	450	409	502	486	452	477	429	502	454	461	388	401
Cost Of Revenue	-4.5%	125	131	125	128	135	127	116	123	117	120	104	127	120	126	189	98.00	111	96.00	97.00	77.00	89.00
Costs and Expenses	-11.5%	560	634	556	536	534	562	508	495	382	516	462	490	461	504	533	470	397	464	457	429	455
S&GA Expenses	-19.6%	226	281	224	215	211	246	217	197	195	218	183	184	174	196	179	175	187	188	170	161	162
R&D Expenses	-0.6%	205	206	191	177	172	173	158	158	161	161	158	161	149	157	147	182	142	173	173	186	184
EBITDA Margin	14.4%	0.14*	0.12*	0.11*	0.09*	0.08*	0.12*	0.10*	0.08*	0.08*	0.02*	0.02*	0.02*	-	-	-	-	-	-	-	-	-
Interest Expenses	-41.8%	4.00	6.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	10.00	8.00	7.00	7.00	3.00	7.00	7.00
Income Taxes	1711.2%	17.00	-1.05	1.00	15.00	6.00	-17.31	5.00	7.00	13.00	-8.68	-9.67	1.00	6.00	-63.89	-846	-13.09	20.00	-24.80	-45.21	-4.46	4.00
Earnings Before Taxes	446.1%	106	19.00	42.00	71.00	57.00	-17.56	-1.90	35.00	134	-66.57	-46.16	14.00	23.00	-46.86	-61.22	-42.27	101	-9.78	10.00	-41.89	-52.96
EBT Margin	23.2%	0.10*	0.08*	0.07*	0.05*	0.03*	0.07*	0.05*	0.03*	0.02*	-0.04*	-0.03*	-0.04*	-	-	-	-	-	-	-	-	-
Net Income	335.2%	89.00	20.00	40.00	56.00	51.00	-0.25	-6.65	28.00	121	-57.90	-36.49	13.00	17.00	17.00	785	-29.18	81.00	15.00	55.00	-37.43	-56.47
Net Income Margin	20.0%	0.08*	0.07*	0.06*	0.04*	0.03*	0.07*	0.04*	0.03*	0.02*	-0.03*	0.01*	0.43*	-	-	-	-	-	-	-	-	-
Free Cashflow	1555.2%	21.00	-1.43	114	48.00	-98.39	-28.90	129	29.00	-74.25	-17.56	78.00	60.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.5%	6,873	6,842	6,758	6,563	6,434	6,375	6,264	6,146	6,063	6,005	5,977	5,898	5,805	5,848	6,158	5,302	4,723	4,690	4,558	4,393	4,435
Current Assets	1.0%	2,985	2,956	2,955	2,950	2,842	2,751	2,683	2,518	2,394	2,274	2,312	2,358	2,289	2,342	2,739	2,648	2,116	1,942	1,859	1,807	1,917
Cash Equivalents	-1.1%	747	755	785	694	580	725	762	620	605	587	617	642	667	649	1,016	819	477	437	423	308	364
Inventory	2.8%	1,138	1,107	1,032	976	919	894	839	802	786	777	749	711	714	699	701	744	706	680	609	579	535
Net PPE	-0.5%	1,060	1,066	1,067	1,067	1,068	1,073	1,052	1,049	1,040	1,035	1,025	1,027	1,022	1,032	1,015	1,011	1,010	1,011	969	963	952
Goodwill	0%	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	196	197	197	197	197
Liabilities	-4.8%	1,799	1,890	1,861	1,780	1,775	1,772	1,696	1,641	1,671	1,739	1,711	1,657	1,643	1,742	2,104	2,065	1,483	1,568	1,484	1,432	1,499
Current Liabilities	-7.6%	1,088	1,177	1,163	597	598	589	521	465	490	546	515	443	430	493	855	813	820	933	494	439	501
Long Term Debt	0.1%	594	593	593	1,085	1,084	1,083	1,082	1,081	1,080	1,079	1,078	1,077	1,076	1,075	1,074	1,073	487	486	844	839	835
LT Debt, Current	0.1%	494	494	493	-	-	-	-	-	-	-	-	-	-	-	374	370	366	362	-	-	-
LT Debt, Non Current	0.1%	594	593	593	1,085	1,084	1,083	1,082	1,081	1,080	1,079	1,078	1,077	1,076	1,075	1,074	1,073	487	486	844	839	835
Shareholder's Equity	2.5%	5,074	4,952	4,897	4,783	4,659	4,603	4,569	4,500	4,386	4,266	4,261	4,237	4,162	4,101	4,054	3,237	3,240	3,122	3,074	2,961	2,937
Retained Earnings	14.3%	-532	-621	-641	-682	-738	-789	-788	-777	-804	-930	-867	-831	-844	-861	-883	-1,668	-1,639	-1,720	-1,735	-1,790	-1,753
Additional Paid-In Capital	0.1%	5,619	5,612	5,543	5,494	5,418	5,405	5,336	5,273	5,206	5,192	5,134	5,084	5,011	4,993	4,938	4,886	4,855	4,833	4,783	4,744	4,683
Accumulated Depreciation	2.4%	888	867	851	829	807	802	782	762	741	721	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.6%	190	189	188	188	187	186	185	185	184	183	183	182	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	10,100	-	-	-	9,000	-	-	-	8,400	-	-	-	13,900	-	-	-	8,100	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	70.9%	46,971	27,483	135,646	70,062	-73,932	6,786	158,321	56,226	-45,431	11,180	97,060	82,784	113,512	-13,384	86,206	27,737	-15,194	57,343	70,125	-24,338	-54,868
Share Based Compensation	6.2%	58,249	54,855	48,387	50,162	53,695	46,734	54,663	47,078	47,833	43,891	49,026	54,843	49,503	47,586	50,169	44,962	46,994	38,102	39,173	39,829	42,761
Cashflow From Investing	78.1%	-14,236	-64,963	-45,799	29,530	-30,012	-54,710	-23,402	-29,699	87,782	-55,421	-119,847	-120,257	-70,788	11,027	106,699	-248,751	77,404	-48,896	48,678	19,671	-50,479
Cashflow From Financing	-494.8%	-42,793	10,840	-788	11,963	-40,742	10,869	7,541	-11,780	-25,280	14,396	-1,031	10,951	-24,364	-366,155	3,256	563,688	-19,671	4,042	-1,975	-51,760	-24,981
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50,000	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BMRN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES:
Total revenues	$ 648,833	$ 596,415
OPERATING EXPENSES:
Cost of sales	125,180	135,472
Research and development	204,987	171,846
Selling, general and administrative	225,906	211,023
Intangible asset amortization	14,298	15,670
Gain on sale of nonfinancial assets	(10,000)	0
Total operating expenses	560,371	534,011
INCOME FROM OPERATIONS	88,462	62,404
Interest income	19,365	11,943
Interest expense	(3,547)	(3,703)
Other income (expense), net	1,267	(13,887)
INCOME BEFORE INCOME TAXES	105,547	56,757
Provision for income taxes	16,885	5,905
NET INCOME	$ 88,662	$ 50,852
EARNINGS PER SHARE, BASIC (in dollars per share)	$ 0.47	$ 0.27
EARNINGS PER SHARE, DILUTED (in dollars per share)	$ 0.46	$ 0.27
Weighted average common shares outstanding, basic (in shares)	188,866	186,667
Weighted average common shares outstanding, diluted (in shares)	199,262	194,363
COMPREHENSIVE INCOME	$ 116,404	$ 43,997
Net product revenues
REVENUES:
Total revenues	637,815	586,426
Royalty and other revenues
REVENUES:
Total revenues	$ 11,018	$ 9,989

BMRN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

^[1]

Current assets:

Cash and cash equivalents

$ 746,996

$ 755,127

Short-term investments

299,584

318,683

Accounts receivable, net

637,163

633,704

Inventory

1,137,982

1,107,183

Other current assets

163,287

141,391

Total current assets

2,985,012

2,956,088

Noncurrent assets:

Long-term investments

620,551

611,135

Property, plant and equipment, net

1,060,425

1,066,133

Intangible assets, net

279,653

294,701

Goodwill

196,199

Deferred tax assets

1,546,043

1,545,809

Other assets

184,790

171,538

Total assets

6,872,673

6,841,603

Current liabilities:

Accounts payable and accrued liabilities

593,543

683,147

Short-term convertible debt, net

494,357

493,877

Total current liabilities

1,087,900

1,177,024

Noncurrent liabilities:

Long-term convertible debt, net

593,605

593,095

Other long-term liabilities

117,352

119,935

Total liabilities

1,798,857

1,890,054

Stockholders’ equity:

Common stock, $0.001 par value: 500,000,000 shares authorized; 189,776,577 and 188,598,154 shares issued and outstanding, respectively

190

189

Additional paid-in capital

5,619,264

5,611,562

Company common stock held by the Nonqualified Deferred Compensation Plan

(11,700)

(9,860)

Accumulated other comprehensive loss

(1,046)

(28,788)

Accumulated deficit

(532,892)

(621,554)

Total stockholders’ equity

5,073,816

4,951,549

^[2]

Total liabilities and stockholders’ equity

$ 6,872,673

$ 6,841,603

[1]	(1)December 31, 2023 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 26, 2024.
[2]	The beginning balances for the three-month periods were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 26, 2024.

About BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

CEO	Mr. Jean-Jacques Bienaime M.B.A., MBA
WEBSITE	biomarin.com
INDUSTRY	Biotechnology
EMPLOYEES	3082

BioMarin Pharmaceutical Inc Frequently Asked Questions

What is the ticker symbol for BioMarin Pharmaceutical Inc? What does BMRN stand for in stocks?

BMRN is the stock ticker symbol of BioMarin Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioMarin Pharmaceutical Inc (BMRN)?

As of Wed May 08 2024, market cap of BioMarin Pharmaceutical Inc is 15.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMRN stock?

You can check BMRN's fair value in chart for subscribers.

What is the fair value of BMRN stock?

You can check BMRN's fair value in chart for subscribers. The fair value of BioMarin Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioMarin Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMRN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioMarin Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether BMRN is over valued or under valued. Whether BioMarin Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact BioMarin Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMRN.

What is BioMarin Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, BMRN's PE ratio (Price to Earnings) is 75.6 and Price to Sales (PS) ratio is 6.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMRN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioMarin Pharmaceutical Inc's stock?

In the past 10 years, BioMarin Pharmaceutical Inc has provided 0.034 (multiply by 100 for percentage) rate of return.